Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218130

SCHEMBL23218130

SCHEMBL23218130

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2ccc(-c3cccc(C#N)n3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.39
▸ KDM4E B2RXH2 5/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ HPGD P15428 4/20 0.39
▸ MAPT P10636 4/20 0.39
▸ GAA P10253 3/20 0.39
▸ GLA P06280 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CTSS P25774 2/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PTPN1 P18031 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ P2RX3 P56373 1/20 0.34
▸ PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852964 0.88 TSHR (0.39) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL23218814 0.88 TSHR (0.39) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL29853105 0.84 ALDH1A1 (0.40) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL23218633 0.84 ALDH1A1 (0.40) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL29340068 0.81 TSHR (0.42) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL23218394 0.81 TSHR (0.38) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL23218533 0.81 CFD (0.43) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL29852791 0.81 CFD (0.43) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL29122740 0.81 TSHR (0.40) TSHRKDM4EALDH1A1HPGDMAPT
SCHEMBL23228999 0.81 CFD (0.42) TSHRKDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885KDM4E 4172/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885KDM4E 4491/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.